Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Amortization of Deferred Charges (2016 - 2025)

Ptc Therapeutics (PTCT) has 13 years of Amortization of Deferred Charges data on record, last reported at $313000.0 in Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges rose 1.95% year-over-year to $313000.0; the TTM value through Dec 2025 reached $1.2 million, up 1.75%, while the annual FY2025 figure was $1.2 million, 1.75% up from the prior year.
  • Amortization of Deferred Charges reached $313000.0 in Q4 2025 per PTCT's latest filing, up from $305000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $585000.0 in Q4 2022 and bottomed at $295000.0 in Q2 2024.
  • Average Amortization of Deferred Charges over 5 years is $401950.0, with a median of $409500.0 recorded in 2022.
  • The widest YoY moves for Amortization of Deferred Charges: up 109.27% in 2021, down 91.72% in 2021.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $471000.0 in 2021, then grew by 24.2% to $585000.0 in 2022, then crashed by 48.89% to $299000.0 in 2023, then increased by 2.68% to $307000.0 in 2024, then rose by 1.95% to $313000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $313000.0 in Q4 2025, $305000.0 in Q3 2025, and $302000.0 in Q2 2025.